


We claim:

1. A compound of Formula I:



wherein X and Y are independently =N-, -NR¹-, CR¹, or -S-, provided that at least one of X and Y is CR¹;

Ring A is a 4- to 7-membered cycloalkyl or heterocycloalkyl or a 5- to 6-membered heteroaryl, wherein up to 2 carbon atoms are replaced with a heteroatom selected from =N-, -NR²-, -O-, -S and any remaining carbon atom may be substituted with R³ as valency allows;

Each R¹ is independently H, C₁₋₄alkyl, C₃₋₆cycloalkyl, -CF₃, -(CH₂)₁₋₃CF₃, 4- to 10-membered heterocycloalkyl, wherein said heterocycloalkyl may be substituted with up to two substituents independently selected from halogen, OH, oxo, cyano, C₁₋₆alkyl, or C₁₋₆alkyl-O-C₁₋₆alkyl;

Each R² is independently H, C₁₋₆alkyl, C₄₋₁₀bicycloalkyl, -(CH₂)_t-CN, -SO₂C₁₋₆alkyl, -SO₂(CH₂)_tC₃₋₆cycloalkyl, -C₁₋₆alkyl-O-C₁₋₆alkyl, -C₁₋₆alkyl-C(O)O-C₁₋₆alkyl, -C₃₋₆cycloalkyl-C(O)O-C₁₋₆alkyl, -C(O)-(O)_u-C₁₋₆alkyl, -C(O)-C₁₋₆alkyl-O-C₁₋₆alkyl, -C(O)-(O)_u-(CH₂)_t-(C₆₋₁₀aryl), -(CH₂)_t-(C₆₋₁₀aryl), -C(O)-(O)_u-(CH₂)_t-(5- to 10-membered heteroaryl), -(CH₂)_t-C(O)-NR⁵R⁶, -(CH₂)_t-(5- to 10-membered heteroaryl), -C(O)-(O)_u-(CH₂)_t-(3- to 10-membered heterocycloalkyl), -(CH₂)_t-(4- to 10-membered heterocycloalkyl), -C(O)-(O)_u-(CH₂)_t-(3- to 10-membered cycloalkyl), or -(CH₂)_t-(3- to 10-membered cycloalkyl),

wherein said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl of R^2 may be substituted with up to two substituents independently selected from halogen, OH, cyano, C_{1-6} alkyl, or C_{1-6} alkyl-O- C_{1-6} alkyl,

and wherein any alkyl, cycloalkyl, and heterocycloalkyl of R^2 may be further substituted with oxo where valency allows;

Each R^3 is independently absent, C_{1-3} alkyl, halogen, oxo, $-NR^5R^6$, or $-OR^5$;

Each R^4 is independently halogen, $-CF_3$, C_{1-3} alkyl, $-(CH_2)_t-C_{3-4}$ cycloalkyl, $-(CH_2)_t-O-C_{1-3}$ alkyl, $-(CH_2)_t$ -cyano, or $-(CH_2)_t$ -hydroxy;

Each R^5 is independently H or C_{1-6} alkyl;

Each R^6 is independently H or C_{1-6} alkyl;

R^7 is H, halogen, or C_{1-3} alkyl;

n is 0, 1, or 2;

Each t is independently 0, 1 or 2; and

Each u is independently 0 or 1,

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R^1 is independently H or C_{1-4} alkyl;

Each R^2 is independently H, C_{1-6} alkyl, $-SO_2C_{1-6}$ alkyl, $-SO_2(CH_2)_tC_{3-6}$ cycloalkyl, $-C_{1-6}$ alkyl-O- C_{1-6} alkyl, $-C(O)-(O)_u-C_{1-6}$ alkyl, $-(CH_2)_t-(C_{6-10}$ aryl), $-C(O)-(O)_u-(CH_2)_t$ -(5- to 10-membered heteroaryl), $-(CH_2)_t-C(O)-NR^5R^6$, $-(CH_2)_t$ -(5- to 10-membered heteroaryl), $-(CH_2)_t$ -(4- to 10-membered heterocycloalkyl), or $-(CH_2)_t$ -(3- to 10-membered cycloalkyl),

wherein said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl of R^2 may be substituted with up to two substituents independently selected from halogen, OH, cyano, C_{1-6} alkyl, $-C(O)-O-C_{1-3}$ alkyl, or C_{1-6} alkyl-O- C_{1-6} alkyl,

and wherein any alkyl, cycloalkyl, and heterocycloalkyl of R^2 may be further substituted with oxo where valency allows;

Each R^3 is independently absent, C_{1-3} alkyl, oxo, $-NR^5R^6$, or $-OR^5$;

R^4 is halogen;

Each R^5 is H;

Each R^6 is independently H or C_{1-6} alkyl;

R^7 is H;


n is 1;

Each t is independently 0, 1 or 2;

Each u is independently 0 or 1;

X, Y, and A are as defined in claim 1.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein A is one of:



and R^2 and R^3 are as defined in any previous claim.


4. The compound of any previous claim, or a pharmaceutically acceptable salt thereof, wherein R_2 is independently H, $-CH_3$, or SO_2CH_3 ; and R^3 is independently absent or oxo.

5. The compound of any previous claim, or a pharmaceutically acceptable salt thereof, wherein X is NR^1 and said R^1 off of N is C_{1-4} alkyl or C_{3-4} cycloalkyl;

Y is CR^1 and said R^1 off of C is H or CH_3 ;

R^4 is F;

A is

and R⁷ is H.

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is

4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)furo[3,4-b]pyridin-5(7H)-one;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-benzyl-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

9-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2,3,4,5-tetrahydropyrido[2,3-f][1,4]oxazepine;

9-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methyl-2,3,4,5-tetrahydropyrido[2,3-f][1,4]oxazepine;

9-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-3-methyl-2,3,4,5-tetrahydropyrido[2,3-f][1,4]oxazepine;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(methylsulfonyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

6-(ethylsulfonyl)-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-propionyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-N-methyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-[(1-methyl-1H-pyrazol-4-yl)methyl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(tetrahydrofuran-3-ylmethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-cyclopentyl-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-ethyl-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-(cyclopropylmethyl)-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

3-{4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-5-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl}propanenitrile;

3-{4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-5-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl}methylbenzonitrile;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-[(1R,5S,6R)-3-oxabicyclo[3.1.0]hex-6-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-bicyclo[1.1.1]pent-1-yl-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(pyridin-3-ylmethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-(3-ethoxypropyl)-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one; or

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-[(6-methylpyridin-3-yl)methyl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one.

7. An inhibitor of CK1 delta or CK1 epsilon, wherein the inhibitor is a compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, for use in the treatment of inhibiting CK1 delta or CK1 epsilon activity.

8. Use of an inhibitor of CK1 delta or CK1 epsilon, wherein the inhibitor is a compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of inhibiting CK1 delta or CK1 epsilon activity.

9. The inhibitor according to claim 7 wherein said inhibition of CK1 delta or CK1 epsilon activity results in a lengthening of the circadian rhythm period.

10. The use according to claim 8 wherein said inhibition of CK1 delta or CK1 epsilon activity results in a lengthening of the circadian rhythm period.

11. A compound of any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof for use in the treatment of a neurological and psychiatric disease or disorder.

12. Use of a compound of any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a neurological and psychiatric disease or disorder.

13. The compound according to claim 11 wherein the disease or disorder is a mood disorder or a sleep disorder.

14. The use according to claim 12 wherein the disease or disorder is a mood disorder or a sleep disorder.


15. The compound according to claim 13 wherein the mood disorder is selected from the group consisting of a depressive disorder and a bipolar disorder.

16. The use according to claim 14 wherein the mood disorder is selected from the group consisting of a depressive disorder and a bipolar disorder.

17. A pharmaceutical composition comprising a compound of any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

CLAIMS


1. A compound of Formula I:



wherein:

X is NR^1 and said R^1 off of N is C_{1-4} alkyl or C_{3-4} cycloalkyl;

Y is CR^1 and said R^1 off of C is H or C_{1-4} alkyl;



Each R^2 is independently H, C_{1-6} alkyl, C_{4-10} -bicycloalkyl, $-(\text{CH}_2)_t\text{CN}$, $-\text{SO}_2\text{C}_{1-6}$ alkyl, $-\text{SO}_2(\text{CH}_2)_t\text{C}_{3-6}$ cycloalkyl, $-\text{C}_{1-6}$ alkyl-O- C_{1-6} alkyl, $-\text{C}_{1-6}$ alkyl-C(O)O- C_{1-6} alkyl, $-\text{C}_{3-6}$ cycloalkyl-C(O)O- C_{1-6} alkyl, $-\text{C(O)}-(\text{O})_u\text{-C}_{1-6}$ alkyl, $-\text{C(O)-C}_{1-6}$ alkyl-O- C_{1-6} alkyl, $-\text{C(O)}-(\text{O})_u\text{-(CH}_2)_t\text{-(C}_{6-10}\text{aryl)}$, $-(\text{CH}_2)_t\text{-(C}_{6-10}\text{aryl)}$, $-\text{C(O)}-(\text{O})_u\text{-(CH}_2)_t\text{-(5- to 10-membered$

heteroaryl), $-(CH_2)_t-C(O)-NR^5R^6$, $-(CH_2)_t$ -(5- to 10-membered heteroaryl),
 $-C(O)-(O)_u-(CH_2)_t$ -(3- to 10-membered heterocycloalkyl),
 $-(CH_2)_t$ -(4- to 10-membered heterocycloalkyl), $-C(O)-(O)_u-(CH_2)_t$ -(3- to 10-membered
cycloalkyl), or $-(CH_2)_t$ -(3- to 10-membered cycloalkyl),

wherein said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl of R^2 may be substituted with up to two substituents independently selected from halogen, OH, cyano, C_{1-6} alkyl, $-C(O)-O-C_{1-3}$ alkyl or C_{1-6} alkyl- $O-C_{1-6}$ alkyl,

and wherein any alkyl, cycloalkyl, and heterocycloalkyl of R^2 may be further substituted with oxo where valency allows;

Each R^3 is independently absent, C_{1-3} alkyl, oxo, $-NR^5R^6$, or $-OR^5$;

Each R^4 is independently halogen;

Each R^5 is independently H or C_{1-6} alkyl;

Each R^6 is independently H or C_{1-6} alkyl;

R^7 is H;

n is 0, 1, or 2;

Each t is independently 0, 1 or 2; and

Each u is independently 0 or 1;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is NR^1 and said R^1 off of N is C_{1-4} alkyl and Y is CR^1 and said R^1 off of C is H or CH_3 ;

Each R^2 is independently H, C_{1-6} alkyl, $-SO_2C_{1-6}$ alkyl, $-SO_2(CH_2)_tC_{3-6}$ cycloalkyl, $-C_{1-6}$ alkyl- $O-C_{1-6}$ alkyl, $-C(O)-(O)_u-C_{1-6}$ alkyl, $-(CH_2)_t$ -(C_{6-10} aryl),
 $-C(O)-(O)_u-(CH_2)_t$ -(5- to 10-membered heteroaryl), $-(CH_2)_t-C(O)-NR^5R^6$,
 $-(CH_2)_t$ -(5- to 10-membered heteroaryl), $-(CH_2)_t$ -(4- to 10-membered heterocycloalkyl),
or $-(CH_2)_t$ -(3- to 10-membered cycloalkyl),

wherein said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl of R^2 may be substituted with up to two substituents independently selected from halogen, OH, cyano, $-C_{1-6}$ alkyl, $-C(O)-O-C_{1-3}$ alkyl, or C_{1-6} alkyl- $O-C_{1-6}$ alkyl,

and wherein any alkyl, cycloalkyl, and heterocycloalkyl of R^2 may be further substituted with oxo where valency allows;


R^4 is F;

Each R^5 is H;

n is 1; and

R^3 , R^6 , R^7 , t, u and A are as defined in claim 1.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein A is one of:



and R^2 and R^3 are as defined in any previous claim.

4. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R^2 is independently H, $-CH_3$, or SO_2CH_3 ; and R^3 is independently absent or oxo.


5. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein R^2 is independently H, $-CH_3$, or SO_2CH_3 ; and R^3 is independently absent or oxo.

6. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein X is NR^1 and said R^1 off of N is C_{1-4} alkyl;

Y is CR^1 and said R^1 off of C is H or CH_3 ;

R^4 is F;

A is




and n is 1.

7. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein X is NR^1 and said R^1 off of N is C_{1-4} alkyl;

Y is CR^1 and said R^1 off of C is H or CH_3 ;


R^4 is F;

A is




and n is 1.

8. A compound according to claim 7, or a pharmaceutically acceptable salt thereof,




wherein ring A is

9. A compound according to claim 7, or a pharmaceutically acceptable salt thereof,




wherein ring A is

10. A compound according to claim 7, or a pharmaceutically acceptable salt thereof,




wherein ring A is

11. A compound according to claim 3, or a pharmaceutically acceptable salt thereof,




wherein Ring A is

12. A compound according to claim 3, or a pharmaceutically acceptable salt thereof,



wherein Ring A is

13. A compound according to claim 3, or a pharmaceutically acceptable salt thereof,



wherein is Ring A is

14. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is:

4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)furo[3,4-b]pyridin-5(7H)-one;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-benzyl-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(methylsulfonyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

6-(ethylsulfonyl)-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-propionyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-[(1-methyl-1H-pyrazol-4-yl)methyl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(tetrahydrofuran-3-ylmethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-cyclopentyl-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-ethyl-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-(cyclopropylmethyl)-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

3-{4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-5-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl}propanenitrile;

3-({4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-5-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl}methyl)benzonitrile;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-[(1R,5S,6r)-3-oxabicyclo[3.1.0]hex-6-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-bicyclo[1.1.1]pent-1-yl-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(pyridin-3-ylmethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-(3-ethoxypropyl)-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one; or

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-[(6-methylpyridin-3-yl)methyl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one.

15. A compound according to claim 1 wherein the compound is:

4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)furo[3,4-b]pyridin-5(7H)-one;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-benzyl-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-benzyl-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(methylsulfonyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

6-(ethylsulfonyl)-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

6-(cyclopropylsulfonyl)-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-propionyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

6-acetyl-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine

6-(cyclopropylacetyl)-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(tetrahydro-furan-3-ylcarbonyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(methoxy-acetyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-isobutyryl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(tetrahydro-2H-pyran-4-ylcarbonyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(pyrimidin-2-ylacetyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

6-(cyclopropylcarbonyl)-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine;

benzyl 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxylate;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-[(1-methyl-1H-pyrazol-4-yl)methyl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(tetrahydrofuran-3-ylmethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(3-methoxypropyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-(2-tert-butoxyethyl)-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

methyl 1-{4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-5-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl}cyclopropanecarboxylate;
 6-cyclopentyl-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-[2-(1-methyl-1H-pyrazol-4-yl)ethyl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;
 6-ethyl-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;
 6-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;
 6-(cyclopropylmethyl)-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-isobutyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;
 3-{4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-5-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl}propanenitrile;
 3-({4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-5-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)methyl}benzonitrile;
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(2-methoxyethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;
 2-{4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-5-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl}-N,N-dimethylacetamide;
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-[(1R,2S)-2-(methoxymethyl)cyclopentyl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-[(1R,5S,6r)-3-oxabicyclo[3.1.0]hex-6-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-[(3S)-2-oxotetrahydrofuran-3-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-[(1R)-1-methylbutyl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-bicyclo[1.1.1]pent-1-yl-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;
 isopropyl {4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-5-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl}acetate;
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(pyridin-3-ylmethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;
 6-(3-ethoxypropyl)-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one; or
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-[(6-methylpyridin-3-yl)methyl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one,
 or a pharmaceutically acceptable salt thereof.

16. A compound according to claim 1 wherein the compound is:

9-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2,3,4,5-tetrahydropyrido[2,3-f][1,4]oxazepine;
 9-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methyl-2,3,4,5-tetrahydropyrido[2,3-f][1,4]oxazepine;
 9-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-3-methyl-2,3,4,5-tetrahydropyrido[2,3-f][1,4]oxazepine; or
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-N-methyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine,
 or a pharmaceutically acceptable salt thereof.

17. The compound according to claim 1 which is 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]furo[3,4-b]pyridin-5(7H)-one or a pharmaceutically acceptable salt thereof.

18. The compound according to claim 5 which is 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]furo[3,4-b]pyridin-5(7H)-one.

19. The compound or pharmaceutically acceptable salt according to claim 5, which is a pharmaceutically acceptable salt of 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]furo[3,4-b]pyridin-5(7H)-one.

20. A compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, for use as a CK1 delta or CK1 epsilon activity inhibitor.
21. Use of an inhibitor of CK1 delta or CK1 epsilon, wherein the inhibitor is a compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a mood disorder or a sleep disorder.
22. The use according to claim 21 wherein said inhibition of CK1 delta or CK1 epsilon activity results in a lengthening of the circadian rhythm period.
23. The use according to claim 22 wherein the sleep disorder is a circadian rhythm sleep disorder that is selected from the group consisting of shift work sleep disorder, jet lag syndrome, advanced sleep phase syndrome and delayed sleep phase syndrome; and the mood disorder is selected from the group consisting of a depressive disorder and a bipolar disorder.
24. The compound of any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof for use in the treatment of a neurological and psychiatric disease or disorder.
25. Use of a compound of any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a neurological or psychiatric disorder that is selected from the group consisting of cerebral deficits subsequent to cardiac bypass surgery and grafting, stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic neuronal damage, dementia, AIDS-induced dementia, vascular dementia, mixed dementias, age-associated memory impairment, Alzheimer's disease, Huntington's Chorea, amyotrophic lateral sclerosis, ocular damage, retinopathy, cognitive disorders, including cognitive disorders associated with schizophrenia and bipolar disorders, idiopathic and drug-induced Parkinson's disease, muscular spasms and disorders associated with muscular spasticity including tremors, epilepsy, convulsions, migraine, migraine headache, urinary incontinence, substance tolerance, substance withdrawal, withdrawal from opiates, nicotine, tobacco products, alcohol, benzodiazepines, cocaine, sedatives, and hypnotics, psychosis, mild cognitive impairment, amnesic cognitive impairment, multi-domain cognitive impairment, obesity, schizophrenia, anxiety, generalized anxiety disorder, social

anxiety disorder, panic disorder, post-traumatic stress disorder, obsessive compulsive disorder, mood disorders, depression, mania, bipolar disorders, trigeminal neuralgia, hearing loss, tinnitus, macular degeneration of the eye, emesis, brain edema, pain, acute and chronic pain states, severe pain, intractable pain, neuropathic pain, post-traumatic pain, tardive dyskinesia, sleep disorders, narcolepsy, attention deficit/hyperactivity disorder, autism, Asperger's disease, and conduct disorder.

26. The use according to claim 24 wherein the disease or disorder is a mood disorder or a sleep disorder.

27. The use according to claim 25 wherein the disease or disorder is a mood disorder or a sleep disorder.

28. The use according to claim 26 wherein the mood disorder is selected from the group consisting of a depressive disorder and a bipolar disorder.

29. The use according to claim 27 wherein the mood disorder is selected from the group consisting of a depressive disorder and a bipolar disorder.

30. A pharmaceutical composition comprising a compound of any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.